Citations

Clear

14 citation(s) found for "Scott, Aaron".

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.
Shroff, Rachna T. , Guthrie, Katherine A. , Scott, Aaron J. , Goff, Laura W. , Matin, Khalid , Kalyan, Aparna, Javle, Milind , Aghajanian, Carol , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Chiorean, E. Gabriela , Höchster, Howard S. , Philip, Philip Agop, Borad, Mitesh J. , Mahipal, Amit , Patel, Anuj , El-Khoueiry, Anthony B.

Mayo Clinic

Journal of Clinical Oncology | September 14, 2023 | Volume: 41 | Issue: 4_suppl | Pages: No page available

10.1200/jco.2023.41.4_suppl.lba490 Get It

LBA490 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Gemcitabine-based regimens are the standard of care in advanced disease, but median overall survival (OS) is roughly 12 months. The addition of albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) demonstrated promising efficacy in a 60 patient, single-arm phase II study (Shroff et al, JAMA Oncol 2019), with observed median OS of 19.2 months. Methods: SWOG 1815 is a randomized, open-label, phase III trial comparing GAP to gemcitabine/cisplatin (GC). The study included newly diagnosed advanced BTC patients (pts), randomized 2:1 to GAP vs. GC. GAP included gemcitabine at 800 mg/m2, cisplatin at 25 mg/m2 and albumin-bound paclitaxel at 100 mg/m2 on days 1 and 8 of a 21-day cycle. GC included standard dosing of gemcitabine at 1000 mg/m2 and cisplatin at 25 mg/m2 on days 1 and 8 of a 21-day cycle. Pts were treated until progression. The primary endpoint was overall survival (OS) with a target hazard ratio of 0.7 with 90% power and a 1-sided alpha of 0.025; randomization was stratified by disease site (intrahepatic cholangiocarcinoma [CCA] vs gallbladder adenocarcinoma [GBC] vs extrahepatic CCA), disease stage (locally advanced vs metastatic), and Zubrod PS 0 vs 1. Results: Of 441 eligible pts randomized, 55% were female. 67% of patients had intrahepatic CCA, 16% had GBC and 17% had extrahepatic CCA. Most pts had metastases (73%). Median OS with GAP vs. GC was 14 vs. 12.7 mo respectively (HR 0.93, 95% CI 0.74-1.19, p=0.58), ORR (confirmed and unconfirmed) 34% vs 25% (p=0.11) and median PFS 8.2 vs 6.4 mo (HR 0.92, 95% CI 0.72-1.16, p=0.47), respectively. Grade 3 and 4 treatment related adverse events (TRAEs) in ≥10% of pts for GAP and GC were anemia, neutropenia, and thrombocytopenia. GAP had more ≥ grade 3 hematologic AEs compared to the GC arm (60% vs. 45%, p=0.003). Discontinuation due to toxicity was at 24% vs 19% (p=0.26) with GAP vs GC. In exploratory subset analyses, GAP vs GC improved OS in pts with locally advanced disease (medians 19.2 vs 13.7 mo; HR 0.67, 95% CI 0.42-1.06, p=0.09) and in GBC pts (medians 17.0 vs 9.3 mo; HR 0.74, 95% CI 0.41-1.35, p=0.33). ORR for GAP vs GC in GBC was 50% vs 24% (p=0.09) and for locally advanced disease 28 vs 21% p=0.74. Conclusions: SWOG 1815 did not result in a statistically significant improvement in median OS with GAP vs. GC. The GAP regimen had higher rates of TRAEs without a statistically significant difference in discontinuation rates. Pts with locally advanced disease and GBC may benefit from the use of GAP. Further analyses are ongoing to understand potential benefit of GAP in subsets of BTC pts. Funding: NIH/National Cancer Institute grants CA180888, CA180819, CA180820, CA180821, and CA180868; and in part by Celgene Corporation, Summit, NJ (subsidiary of Bristol Myer Squibb). Clinical trial information: NCT#03768414 .
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
Sonbol, Bassam Bassam, Uronis, Hope E. , Chiu, Vi K., Scott, Aaron J. , Iqbal, Syma , Tejani, Mohamedtaki Abdulaziz, Stilian, Melissa C, Thoma, Mathis, Kagey, Michael H. , Baum, Jason , Sirard, Cynthia A. , Altura, Rachel A., Klempner, Samuel J. , Wainberg, Zev A. , Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 4027-4027

10.1200/jco.2023.41.16_suppl.4027 Get It

4027 Background: DKN-01 is an anti-DKK1 mAb which has demonstrated anti-tumor activity in patients with advanced GEA with low tumor PD-L1 expression, a subset with very limited therapeutic options. DKN-01 has immunomodulatory activity, stimulates a pro-inflammatory tumor microenvironment, and upregulates PD-L1 levels. Here we present 2-year survival data for 1L advanced GEA patients who received combination treatment with DKN-01, the Fc-optimized anti-PD-1 tislelizumab, and CAPOX chemotherapy. The ORR was previously reported (68% in ITT and 79% in PD-L1-low populations). Methods: This Phase 2, multi-center, single arm Part A of the DisTinGuish (NCT04363801) study investigated DKN-01 + tislelizumab + CAPOX as 1L therapy in advanced HER2(-) GEA, regardless of DKK1 and PD-L1 expression levels. Tumor DKK1 and PD-L1 were assessed by central laboratories. The primary endpoint was ORR in a modified intent to treat population (>1 dose DKN-01); secondary endpoints included PFS and OS in the ITT population. Results: Twenty-five patients were enrolled from September 2020 to April 2021. As of 23 January 2023: Median age was 61 years (22, 80); 17 patients had GEJ adenocarcinoma; 8 had gastric cancer. Twenty-one patients had tumors with evaluable DKK1 expression. Twenty-two patients had tumors with evaluable PD-L1 expression; the majority (73%) were low expressors (vCPS <5%). Median (m) duration on treatment is 11.3 months (mo). Seven patients remain on study, with 4 on-treatment beyond 2 years. The mPFS is 11.3 mo in the overall ITT population and 10.7 mo in patients with low tumor PD-L1 expression. The mOS is 19.5 mo in the overall ITT population and 18.7 mo in the patients with low tumor PD-L1 expression. Treatment related adverse events (TRAEs) were mild with most G1/2. The most common AEs related to the study drug regimen were nausea (72%), diarrhea (64%) and fatigue (60%). Five patients experienced G3 DKN-01-TRAEs including decreased neutrophil count (1), diarrhea (1), vomiting (1), hypophosphatemia (2), and pulmonary embolism (1). Conclusions: At 2-years of follow-up, 1L treatment of advanced GEA patients with DKN-01 in combination with tislelizumab and CAPOX resulted in a prolongation of PFS and OS compared with the modern SOC regimen of nivolumab plus chemotherapy, both in the overall population (mPFS 11.3 vs 7.7 mo; mOS 19.5 vs 13.8 mo) and in the PD-L1 low subgroup (mPFS 10.7 vs 7.5 mo; mOS 18.7 vs 12.4 mo), alongside a manageable safety profile. The prolonged PFS and OS observed in the current study are notable, especially in our trial population dominated by patients with tumors of low PD-L1 expression, where the known benefit of anti-PD-1 therapy is limited. The ongoing Part C of this study is evaluating mFOLFOX6/CAPOX plus tislelizumab with or without DKN-01 in the same 1L GEA patient population. Further evaluation of biomarkers is also ongoing. Clinical trial information: NCT04363801 .
Analyzing the efficacy and safety of immunotherapy in pancreatic ductal adenocarcinoma (PDA): A systematic review and meta-analysis.
Zahid, Umar, Scott, Aaron J. , Elliott, Cynthia M, Boiles, Alejandro Recio, Elquza, Emad , Mahadevan, Daruka , Babiker, Hani M. , Howe, Carol , Riaz, Irbaz Bin , Acharya, Utkarsh

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 512-512

10.1200/jco.2018.36.4_suppl.512 Get It

512 Background: The tumor microenvironment in PDA is heterogeneous and immunosuppressive given the presence of regulatory T cells and exhausted effector T cells. Despite the upsurge of effective immunotherapeutic agents (IA) in other tumor types, the role in PDA remains unknown. We conducted a meta-analysis of IA in PDA. Methods: Following PRISMA guidelines, we searched PubMed/MEDLINE, Elsevier/Embase, Wiley/Cochrane Library and ClinicalTrials.gov. Articles were selected per the following criteria: (1) Study participants had a diagnosis of PDA; (2) An IA was used in the trial. Titles, abstracts and full text articles were reviewed by 2 independent reviewers; disagreements were resolved by a third. Data extraction and analysis were performed by 3 independent reviewers. Descriptive analysis, mean, median, confidence interval and forest plots were used for statistical analysis. Results: We found 20,792 studies through the database, 16,105 remained after duplicates were removed and 15,889 were excluded due to irrelevance. Strict inclusion criteria were applied to the full text of 216 articles. The most common reason for exclusion were conference abstracts (44%) and ongoing trials (16%). Fifty-four trials (39 metastatic (met), 12 adjuvant (Ad) and 3 neoadjuvant (nAd) met criteria for further analysis. Age range was 27-86 (median 61) and 52.3% were males. IA included cytokine therapy (33%), peptide vaccines (22%), dendritic cell vaccine (13%), oncolytic viruses (9%), CTLA-4 inhibitors (2%) and others. IA in met-PDA had a median overall survival (mOS) of 8.1 months (ms) and a disease control rate (DCR) of 55.4% (95% CI, 51.85-58.95). There was no statistical difference in DCR among IA subtypes (range 49-60%) (p = 0.22). The mOS of Ad-PDA trials was 25 ms (historically comparable to gemcitabine, p = 0.75) and 18 ms for nAd-PDA. The most common Gr1/2 toxicities were skin reactions, fever, and chills and Gr3/4 were cytopenias, diarrhea, and mucositis. One death occurred due to neutropenic sepsis. Conclusions: IA demonstrates modest efficacy in the treatment of met-PDA albeit exhibits a favorable toxicity profile. Many trial results are available only in abstract format and some are ongoing.
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Théry, Clotilde , Witwer, Kenneth W. , Aïkawa, Elena , Alcaraz, María José , Anderson, Johnathon D. , Andriantsitohaina, Ramaroson , Antoniou, Anna , Arab, Tanina , Archer, Fabienne , Atkin‐Smith, Georgia K. , Ayre, D. Craig , Bach, Jean‐Marie , Bachurski, Daniel , Baharvand, Hossein , Balaj, Leonora , Baldacchino, Shawn , Bauer, Natalie , Baxter, Amy A. , Bebawy, Mary , Beckham, Carla, Zavec, Apolonija Bedina, Benmoussa, Abderrahim , Berardi, Anna C. , Bergese, Paolo , Bielska, Ewa , Blenkiron, Cherie , Bobis‐Wozowicz, Sylwia , Boilard, Éric , Boireau, Wilfrid , Bongiovanni, Antonella , Borràs, Francesc E. , Bösch, Steffi , Boulanger, Chantal M. , Breakefield, Xandra O. , Breglio, Andrew , Brennan, Meadhbh Á. , Brigstock, David R. , Brisson, Alain , Broekman, Marike L. D. , Bromberg, Jacqueline , Bryl‐Górecka, Paulina , Burger, Dylan , Busatto, Sara , Buschmann, Dominik , Buzás, Edit I. , Byrd, James Brian , Carter, David R. F. , Caruso, Sarah , Chamley, Lawrence W. , Cheng, Lesley , Chin, Andrew R., Clayton, Aled , Clerici, Stefano Piatto , Cocks, Alex, Cocucci, Emanuele , Coffey, Robert J., Cordeiro‐da‐Silva, Anabela , Couch, Yvonne , Coumans, Frank A. W., Coyle, Beth , Crescitelli, Rossella , Criado, Miriã Ferreira, D’Souza‐Schorey, Crislyn , Chaudhuri, Amrita Datta , Candia, Paola de , Santana, Eliezer F De , Wever, Olivier De , Portillo, Hernando A. del , Demaret, Tanguy , Deville, Sarah , Devitt, Andrew , Dhondt, Bert , Vizio, Dolores Di , Rubio, Ana Paula Domínguez , Dourado, Maurício Rocha , Driedonks, Tom A. P. , Duarte, Filipe V. , Duncan, Heather M. , Eichenberger, Ramon M. , Ekström, Karin M. , Andaloussi, Samir EL , Élie-Caille, Céline , Erdbrügger, Uta , Fatima, Farah , Fish, Jason E. , Flores‐Bellver, Miguel , Försönits, András, Frelet‐Barrand, Annie , Fricke, Fabia , Fuhrmann, Gregor , Gámez‐Valero, Ana , Gardiner, Chris , Gärtner, Kathrin , Gaudin, Raphaël , Gho, Yong Song , Giebel, Bernd , Gilbert, Caroline , Gimona, Mario , Giusti, Ilaria , Goberdhan, Deborah C. I. , Görgens, André , Gorski, Sharon M. , Greening, David W. , Gross, Julia Christina , Gualerzi, Alice , Gupta, Gopal N. , Gustafson, Dakota , Handberg, Aase , Haraszti, Reka A. , Harrison, Paul , Hegyesi, Hargita , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Hoffmann, Karl F. , Holder, Beth , Holthöfer, Harry , Hosseinkhani, Baharak , Hu, Guoku , Huang, Yiyao , Huber, Veronica , Hunt, Stuart , Ibrahim, Ahmed , Ikezu, Tsuneya , Inal, Jameel M. , Işın, Mustafa , Ivanova, Alena , Jackson, Hannah K. , Jacobsen, Søren , Jay, Steven M. , Jayachandran, Muthuvel , Jenster, Guido , Jiang, Lanzhou , Johnson, Suzanne M. , Jones, Jennifer , Jong, Ambrose, Jovanović‐Talisman, Tijana , Jung, Stephanie , Kalluri, Raghu , Kano, Shin‐ichi , Kaur, Sukhbir , Kawamura, Yumi , Keller, Evan T. , Khamari, Delaram , Khomyakova, Elena , Kierulf, Peter, Kim, Kwang Pyo , Kislinger, Thomas , Klingeborn, Mikael , Klinke, David J. , Kornek, Miroslaw , Kosanović, Maja , Kovács, Árpád Ferenc , Krämer‐Albers, Eva‐Maria , Krause, Mirja, Kurochkin, Igor V. , Kuypers, Sören , Laitinen, Saara , Langevin, Scott M. , Languino, Lucia R. , Lässer, Cecilia , Laurent, Louise C. , Lázaro‐Ibáñez, Elisa , Lay, Soazig Le , Lee, Myung‐Shin , Lee, Yi , Lemos, Débora S., Lenassi, Metka , Leszczynska, Aleksandra , Li, Isaac T. S. , Liao, Ke , Libregts, Sten F.W.M. , Ligeti, Erzsébet , Lim, Rebecca , Lim, Sai Kiang , Linē, Aija , Linnemannstöns, Karen, Llorente, Alicia , Lorenowicz, Magdalena J. , Lőrincz, Ákos M. , Lovett, Jason , Lowry, Michelle C., Loyer, Xavier , Lu, Quan , Łukomska, Barbara , Lunavat, Taral R. , Marcilla, Antonio , Mariani, Jacopo , Mariscal, Javier , Martens‐Uzunova, Elena S. , Martín‐Jaular, Lorena , Martínez, Maria Carmen , Martins, Vilma R. , Mathieu, Mathilde , Mathivanan, Suresh , Maugeri, Marco , McGinnis, Lynda K. , McVey, Mark J. , Meckes, David G. , Meehan, Katie , Jørgensen, Maléne Møller , Morhayim, Jess , Muraca, Maurizio , Musante, Luca , Mussack, Veronika , Muth, Dillon C. , Myburgh, Kathryn H. , Najrana, Tanbir , Nawaz, Muhammad , Nazarenko, Irina , Nejsum, Peter , Néri, Christian , Nolan, John P. , Hoen, Esther Nm Nolte-'t, Hooten, Nicole Noren , O’Grady, Tina , Ochiya, Takahiro , Olivier, Martin , Ortíz, Alberto , Ortiz, Luis A. , Osteikoetxea, Xabier , Østergaard, Ole , Ostrowski, Matías , Pegtel, D. Michiel , Peinado, Héctor , Perut, Francesca , Pfaffl, Michael W. , Phinney, Donald G. , Pieters, Bartijn C. H. , Pink, Ryan , Pisetsky, David S. , Strandmann, Elke Pogge von , Polakovičová, Iva , Poon, Ivan K. H. , Powell, Bonita H. , Prada, Ilaria , Pulliam, Lynn , Quesenberry, Peter J. , Radeghieri, Annalisa , Raffaı̈, Robert L. , Rak, Janusz , Ramirez, Marcel I. , Raposo, Graça , Rayyan, Morsi , Ricklefs, Franz , Roberts, David D. , Rodrigues, Sílvia C. , Rohde, Eva , Rome, Sophie , Rouschop, Kasper M.A. , Rughetti, Aurelia , Russell, Ashley E. , Sahoo, Susmita , Salas‐Huenuleo, Edison , Sánchez, Catherine , Saugstad, Julie A. , Saul, Meike J. , Schneider, Raphaël , Schøyen, Tine Hiorth , Scott, Aaron , Shahaj, Eriomina , Sharma, Shivani , Shatnyeva, Olga , Shekari, Faezeh , Shelke, Ganesh Vilas , Shiba, Kiyotaka , Siljander, Pia , Silva, Andreia , Skowronek, Agata, Snyder, Orman L., Sódar, Barbara W., Soekmadji, Carolina , Stahl, Philip D., Stoorvogel, Willem , Stott, Shannon L. , Strasser, Erwin , Tahara, Hidetoshi , Tewari, Muneesh , Timms, Kate , Tiwari, Swasti , Tixeira, Rochelle , Toh, Wei Seong , Tomasini, Richard , Tosar, Juan Pablo , Toxavidis, Vasilis, Urbanelli, Lorena , Vader, Pieter , Balkom, Bas WM van, Grein, Susanne G van der, Deun, Jan Van , Herwijnen, Martijn J. C. van , Keuren‐Jensen, Kendall Van , Niel, Guillaume van , Royen, Martin E. van , Wijnen, André J. van , Vasconcelos, M. Helena , Vechetti, Ivan J. , Vella, Laura J. , Velot, Émilie , Verweij, Frederik J. , Vestad, Beate , Viñas, Jose L. , Visnovitz, Tamás , Vukman, Krisztina V , Wahlgren, Jessica, Watson, Dionysios C. , Wauben, Marca H. M. , Weaver, Alissa M. , Webber, Jason , Weber, Viktoria , Wehman, Ann M. , Welsh, Joshua A , Wheelock, Åsa M. , Wiener, Zoltán , Witte, Leonie , Wolfram, Joy , Xagorari, Angeliki , Xander, Patrícia , Xu, Jing , Yan, Xiaomei , Yin, Hang , Yuana, Yuana, Zappulli, Valentina , Zárubová, Jana , Žėkas, Vytautas , Zhang, Jianye , Zhao, Zezhou , Zickler, Antje M. , Zimmermann, Pascale , Zivkovic, Angela M. , Zocco, Davide, Zuba‐Surma, Ewa , Malhi, Harmeet , Peinado, Héctor , van Wijnen, Andre J , Bergese, Paolo , Kim, Kwang Pyo , Ikezu, Tsuneya , Wolfram, Joy , Lenassi, Metka , Gualerzi, Alice , Nazarenko, Irina , Pink, Ryan , Siljander, Pia R-M , Welsh, Joshua A , Witwer, Kenneth W , Hill, Andrew F , Coyle, Beth , Saugstad, Julie A , Buch, Shilpa J. , Buck, Amy H. , Bussolati, Benedetta , Camussi, Giovanni , Chang, Yu‐Ting , Chen, Chihchen , Chen, Daiwen , Criado, Miriã Ferreira , Das, Saumya , Dieterich, Lothar C. , Dolo, Vincenza , Dominici, Massimo , Falcón‐Pérez, Juan Manuel , Gabrielsson, Susanne , Khvorova, Anastasia , Krasemann, Susanne , Kusuma, Gina Diamanta , Lannigan, Joanne , Laurent, Louise C , Lavieu, Grégory , Lombard, Catherine Anne , Lötvall, Jan , Maas, Sybren L. N. , Mertens, Inge , Minciacchi, Valentina R. , Möller, Andreas , Morales‐Kastresana, Aizea , Mullier, François , Neri, Tommaso , Nieuwland, Rienk , Nimrichter, Leonardo , O’Driscoll, Lorraine , O’Loghlen, Ana , Park, Jaesung , Raimondo, Stefania , Regev‐Rudzki, Neta , Robbins, Paul D. , Saá, Paula , Schiffelers, Raymond Michel , Shetty, Ashok Kumar , Soares, Rodrigo Pedro , Sotillo, Javier , Swift, Simon , Tkach, Mercedes , Torrecilhas, Ana Cláudia , Balkom, Bas W. M. van , Grein, Susanne G. van der, Veit, Tiago Degani , Weiss, Daniel J. , Wendt, Sebastian, Yáñez‐Mó, María , Zheng, Lei , Zheutlin, Alexander R. , Borràs, Francesc E , Martens-Uzunova, Elena S , Buzas, Edit I , Giebel, Bernd , Jones, Jennifer C , Ortiz, Alberto , Greening, David W

Mayo Clinic

Journal of Extracellular Vesicles | November 24, 2018 | Volume: 7 | Issue: 1 | Pages: No page available

10.1080/20013078.2018.1535750 | PMID 30637094 Get It

ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.